BioPharma Clinical Trials
Acepodia Secures FDA IND Clearance for ACE1831, Pioneering Gamma Delta T Cell Therapy in Autoimmune Disease
IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T...
November 18, 2024 | News
Ascentage Pharma’s Lisaftoclax NDA Accepted for Priority Review in China: A Potential First for Bcl-2 Inhibitors
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unm...
November 18, 2024 | News
Medidata and Bioforum Expand Partnership to Enhance AI-Driven Clinical Trials for Biotech Clients
-Medidata, a Dassault Systèmes brand and a leading provider of clinical trial solutions for the life sciences industry announced a new corporate agr...
November 18, 2024 | News
Mabwell's Nectin-4 Targeting ADC Secures IND Approval for Clinical Trials in Perioperative Urothelial Carcinoma and Advanced Solid Tumors
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its novel Nectin-4 targeting ADC (R&D code: 9MW...
November 15, 2024 | News
Perth’s Lixa Kicks Off Clinical Trial for NeoX-101, Aiming to Combat Chronic Lung Infections
Lixa, a Perth-based biotechnology company, has announced the launch of its first clinical trial to evaluate the safety and tolerability of NeoX-101, an inn...
November 14, 2024 | News
Nxera Pharma Secures $3.5M Milestone as Centessa Pharmaceuticals Launches Phase 2 Trial of ORX750 for Sleep Disorders
Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes t...
November 14, 2024 | News
Transgene and NEC Unveil Positive 24-Month Data for TG4050 Cancer Vaccine in Adjuvant Treatment of Head and Neck Cancer at SITC 2024
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Cor...
November 14, 2024 | News
Taiwan's Caliway Biopharmaceuticals Receives EMA Orphan Drug Designation for CBL-514 in Dercum’s Disease Treatment
CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease treatment.- CBL-514 received both FDA Orphan Drug...
November 14, 2024 | News
Ascletis Completes Enrollment for Phase III Trial of ASC40 in Acne
Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 Ascletis Pharma Inc. ann...
November 13, 2024 | News
Alphamab Oncology’s JSKN033 Receives Fast-Track Approval from Shanghai Drug Authority for Innovative Cancer Therapy Clinical Trials
Alphamab Oncology (stock code: 9966.HK) announced that a clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulatio...
November 13, 2024 | News
Nordic Bioscience Secures FDA Letter of Support for CPa9-HNE Biomarker in Advancing IBD Clinical Trials
Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a Letter of Support (LoS) from the U.S. Food and Drug ...
November 12, 2024 | News
China’s Gan & Lee’s GZR18 Injection Achieves Up to 17.8% Weight Loss in Phase 2b Trial
Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean ...
November 12, 2024 | News
Harbour BioMed Files IND Application in China for Novel Antibody Therapy HBM9378/SKB378 Targeting COPD
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ant...
November 11, 2024 | News
Dizal Submits NDA to U.S. FDA for Sunvozertinib as a New Treatment Option for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announ...
November 11, 2024 | News
Most Read
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
